GlassScriptPhysician profile
Kristie E Mcdowell
NPI 1275574279
$4,230.09
in general payments reported to CMS, 2019-2025
35 companies · $741 in 2025
The $741 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $667 · 2022: $800 · 2023: $1,193 · 2024: $829 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.65 | 2021-2025 | |
| Novo Nordisk INC | $506.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $403.94 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $378.40 | 2021-2025 | Mounjaro, Emgality, Reyvow |
| Astrazeneca Pharmaceuticals LP | $252.73 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $205.10 | 2022-2025 | |
| Lundbeck LLC | $201.53 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $196.37 | 2022-2025 | |
| Amgen INC. | $150.55 | 2021-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $137.70 | 2021-2023 | |
| Glaxosmithkline, LLC. | $129.95 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $117.35 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $116.79 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $75.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.50 | 2021-2024 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.70 | 2021-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $55.33 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $45.76 | 2022 | |
| Sunovion Pharmaceuticals INC. | $43.73 | 2021-2022 | |
| Corium, LLC | $41.11 | 2023 | Azstarys |
| Amarin Pharma, INC. | $39.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.03 | 2023 | Jardiance |
| Esperion Therapeutics, INC. | $31.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.11 | 2021 | |
| Dexcom, INC. | $25.19 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $21.85 | 2023 | Veozah |
| Horizon Therapeutics Plc | $21.41 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.81 | 2022 | |
| Merck Sharp & Dohme LLC | $19.27 | 2023 | Verquvo, Lagevrio, Belsomra |
| Inspire Medical Systems, INC. | $18.90 | 2023 | Inspire |
| Philips North America LLC | $18.13 | 2024 | (Ck6) Holter |
| Mycovia Pharmaceuticals, INC. | $15.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.04 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristie Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.